SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer

NCT06583070 · clinicaltrials.gov ↗

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Radiation Therapy
Metastatic Renal Cancer
Recurrent Renal Cell Cancer

Interventions

RADIATION: Radiation therapy
DRUG: Targeted and immunotherapy

Sponsor

Peking University First Hospital

Collaborators

[object Object]